These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 38530491

  • 1. Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA.
    Yamamoto T, Kasahara M, Ueshima K, Uemura S, Kashihara N, Kimura K, Konta T, Shoji T, Mima A, Mukoyama M, Saito Y.
    Clin Exp Nephrol; 2024 Aug; 28(8):764-772. PubMed ID: 38530491
    [Abstract] [Full Text] [Related]

  • 2. Intensive uric acid-lowering therapy in CKD patients: the protocol for a randomized controlled trial.
    Kasahara M, Kuwabara Y, Moriyama T, Tanabe K, Satoh-Asahara N, Katsuya T, Hiramitsu S, Shimada H, Sato T, Saito Y, Nakagawa T.
    Clin Exp Nephrol; 2020 Mar; 24(3):235-241. PubMed ID: 31729647
    [Abstract] [Full Text] [Related]

  • 3. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
    Sezai A, Unosawa S, Taoka M, Osaka S, Sekino H, Tanaka M.
    Ann Thorac Cardiovasc Surg; 2020 Aug 20; 26(4):202-208. PubMed ID: 31748427
    [Abstract] [Full Text] [Related]

  • 4. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
    Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, Hayashi Y, Asahi K, Terawaki H, Watanabe T.
    Clin Exp Nephrol; 2015 Dec 20; 19(6):1044-53. PubMed ID: 25676011
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
    Matsuo H, Ishikawa E, Machida H, Mizutani Y, Tanoue A, Ohnishi T, Murata T, Okamoto S, Ogura T, Nishimura Y, Ito H, Yasutomi M, Katayama K, Nomura S, Ito M.
    Clin Exp Nephrol; 2020 Apr 20; 24(4):307-313. PubMed ID: 31845065
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
    Horino T, Hatakeyama Y, Ichii O, Matsumoto T, Shimamura Y, Inoue K, Terada Y, Okuhara Y.
    Clin Exp Nephrol; 2018 Apr 20; 22(2):337-345. PubMed ID: 28752287
    [Abstract] [Full Text] [Related]

  • 9. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
    Wada T, Hosoya T, Honda D, Sakamoto R, Narita K, Sasaki T, Okui D, Kimura K.
    Clin Exp Nephrol; 2018 Aug 20; 22(4):860-870. PubMed ID: 29372470
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T, Ogawa Y, Hashimoto H, Ohashi T, Sakamoto R.
    J Clin Pharm Ther; 2016 Jun 20; 41(3):290-7. PubMed ID: 27109450
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia.
    Pingali U, Nutalapati C, Koilagundla N, Taduri G.
    BMC Complement Med Ther; 2020 Sep 15; 20(1):281. PubMed ID: 32933504
    [Abstract] [Full Text] [Related]

  • 20. Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
    Szczurek P, Mosiichuk N, Woliński J, Yatsenko T, Grujic D, Lozinska L, Pieszka M, Święch E, Pierzynowski SG, Goncharova K.
    PLoS One; 2017 Sep 15; 12(6):e0179195. PubMed ID: 28594873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.